Next Article in Journal
Structurally Modified Bioactive Peptide Inhibits SARS-CoV-2 Lentiviral Particles Expression
Next Article in Special Issue
Co-Delivery of Dihydroartemisinin and Indocyanine Green by Metal-Organic Framework-Based Vehicles for Combination Treatment of Hepatic Carcinoma
Previous Article in Journal
NIL10: A New IL10-Receptor Binding Nanoparticle That Induces Cardiac Protection in Mice and Pigs Subjected to Acute Myocardial Infarction through STAT3/NF-κB Activation
Previous Article in Special Issue
Fabrication, In Vitro, and In Vivo Assessment of Eucalyptol-Loaded Nanoemulgel as a Novel Paradigm for Wound Healing
 
 
Article
Peer-Review Record

Internal Mammary Arteries as a Model to Demonstrate Restoration of the Impaired Vasodilation in Hypertension, Using Liposomal Delivery of the CYP1B1 Inhibitor, 2,3′,4,5′-Tetramethoxystilbene

Pharmaceutics 2022, 14(10), 2046; https://doi.org/10.3390/pharmaceutics14102046
by Azziza Zaabalawi 1, Lewis Renshall 2,3,4, Frances Beards 2,3,4, Adam P. Lightfoot 1,5, Hans Degens 1,6, Yvonne Alexander 1, Ragheb Hasan 7, Haris Bilal 7, Brigitte A. Graf 8, Lynda K. Harris 2,3,4 and May Azzawi 1,*
Reviewer 1: Anonymous
Reviewer 2:
Pharmaceutics 2022, 14(10), 2046; https://doi.org/10.3390/pharmaceutics14102046
Submission received: 26 August 2022 / Revised: 20 September 2022 / Accepted: 22 September 2022 / Published: 26 September 2022

Round 1

Reviewer 1 Report

In this manuscript, Azzawi and coworkers studied the liposomal delivery of 2,3’,4,5’-tetramethoxystilbene (TMS) to determine the inhibition of P450 enzyme CYP1B1 and subsequent vasodilation of IMAs from CABG patients with PEGylated liposomes. The proposed mechanism was carefully evaluated in an ex vivo model of hypertension. Overall, the manuscript is well-written, and the experiments are well designed. The reviewer thinks this work is an important finding in the field and suits the scope of Pharmaceutics. However, below are some minor suggestions the authors can think about to improve the manuscript further:

1.    In Figures 1B-1F and Figure 3F, some of the curves overlap with the x-axis, making them hard to read. The authors should work on the figures to avoid this issue. 

2.    In section 2.1, the authors mentioned the encapsulation efficiency and cited ref 17. However, it seems no such info is included in ref 17, and they were dealing with different content. Also, 50% is an exceptional high encapsulation efficiency (%EE) for passively encapsulated hydrophobic contents. Since %EE can be different from system to system, it would be better if the authors could measure this value again instead of just citing the previous literature. 

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

See attachment. 

Comments for author File: Comments.pdf

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 3 Report

1. 2.1. Synthesis of TMS-Loaded Liposomes: Please rewrite the process of manufacturing liposomes clearly, so can be possible to reproduce by other researchers. What was the size of blank and loaded liposomes, mention in the discussion?

2. Were liposomes prepared for injectable route or oral, please mention in the manuscript?

3. 2.3.1. Human Internal Mammary Artery (IMA) Functional Studies and 2.3.2. Rat Coronary Artery Functional Studies, can this experiment possible to perform in others animal artery, if yes, then which animal can use? What is the correlation between human mammary artery and rat coronary artery?

 

 

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop